Management of multiple sclerosis patients treated with peroral cladribine after four years from the beginning of treatment

Česká verzia

Authors: P. Turčáni ¹; A. Cimprichová ²; A. Cvengrošová ³; V. Donáth ⁴; V. Hančinová ⁵; F. Jurčaga ⁶; E. Kantorová ⁷; E. Klímová ³; P. Koleda ⁸; S. Kováčová ⁹; G. Krastev ¹⁰; D. Slezáková ¹¹; J. Szilasiová ¹²; M. Vítková ¹²
Authors place of work: I. neurologická klinika LF UK a UN Bratislava, Slovensko ¹; Neurologické oddelenie FN Trenčín, Slovensko ²; Neurologické oddelenie FNsP J. A. Reimana Prešov, Slovensko ³; II. neurologická klinika SZU a FNsP FDR Banská Bystrica, Slovensko ⁴; Neurologická klinika SZU a UN Bratislava, Slovensko ⁵; Neurologická klinika SZU UN-Nemocnica sv. Michala Bratislava, Slovensko ⁶; Neurologická klinika JLF a UN Martin, Slovensko ⁷; Neurologická klinika UVN-FN Ružomberok, Slovensko ⁸; Neurologická klinika FN Nitra, Slovensko ⁹; Neurologické oddelenie FN Trnava, Slovensko ¹⁰; II. neurologická klinika LF UK a UN Bratislava, Slovensko ¹¹; Neurologická klinika LF UPJŠ a UNLP Košice, Slovensko ¹²
Published in the journal: Cesk Slov Neurol N 2023; 86(4): 283-285
Category:
doi: https://doi.org/10.48095/cccsnn2023283

Zdroje

1. Giovannoni G, Comi G, Cook S et al. A Placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010; 362 (5): 416–426. doi: 10.1056/NEJMoa0902533.

2. Comi G, Cook S, Giovannoni G et al. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult Scler Relat Disord 2019; 29: 168–174. doi: 10.1016/j.msard.2019.01.038.

3. Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol 2011; 34 (1): 28–35. doi: 10.1097/ WNF.0b013e318204cd90.

4. Giovannoni G, Mathews J. Cladribine tablets for relapsing-remitting multiple sclerosis: a clinician’s review. Neurol Ther 2022; 11 (2): 571–595. doi: 10.1007/s40120-022-00339-7.

5. European Medicines Agency. Súhrn charakteristických vlastností lieku. Mavenclad. [online]. Available from: https: //www.ema.europa.eu/en/documents/product-information/mavenclad-epar-product-information_sk.pdf.

6. Giovannoni G, Soelberg Sorensen P, Cook S et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Mult Scler J 2018; 24 (12): 1594–1604. doi: 10.1177/1352458517727603.

7. Giovannoni G, Aydemir A, Cantogno EVD et al. CLASSIC-MS: Long-term efficacy and real-world treatment patterns for patients with relapsing multiple sclerosis who received cladribine tablets in phase III parent trials (1919). [online]. Available from: https: //n.neurology.org/content/96/15_Supplement/1919.

8. Meca-Lallana V, García Domínguez JM, López Ruiz R et al. Expert-agreed practical recommendations on the use of cladribine. Neurol Ther 2022; 11 (4): 1475–1488. doi: 10.1007/s40120-022-00394-0.

9. Meuth SG, Bayas A, Kallmann B et al. Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4. Expert Opin Pharmacother 2022; 23 (13): 1503–1510. doi: 10.1080/14656566.2022.2106783.

10. Habek M, Drulovic J, Brecl Jakob G et al. Treatment with cladribine tablets beyond year 4: a position statement by southeast european multiple sclerosis centers. Neurol Ther 2023; 12 (1): 25–37. doi: 10.1007/s40120-022-00422-z.

11. Ministerstvo zdravotníctva SR. Zoznam kategorizovaných liekov 1. 5. 2023 – 31. 5. 2023. [online]. Dostupné z: https: //www.health.gov.sk/Zdroje?/Sources/kategorizacia/zkl/202305/cast_B_ind_obmedzenia_k_-01_05_ 2023.rtf.

12. Meuth SG, Bayas A, Kallmann B et al. Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion. Expert Opin Pharmacother 2020; 21 (16): 1965–1969. doi: 10.1080/ 14656566.2020.1792885.